NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free OPT Stock Alerts $3.36 -0.02 (-0.59%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$3.36▼$3.4950-Day Range$2.88▼$4.1452-Week Range$1.60▼$4.42Volume1,950 shsAverage Volume23,802 shsMarket Capitalization$196.22 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Opthea alerts: Email Address Opthea MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside316.7% Upside$14.00 Price TargetShort InterestHealthy0.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.57) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector624th out of 910 stocksBiological Products, Except Diagnostic Industry106th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingOpthea has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOpthea has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.22% of the outstanding shares of Opthea have been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Opthea has recently decreased by 5.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Opthea this week, compared to 0 articles on an average week.Search Interest1 people have searched for OPT on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($2.57) to ($2.25) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Opthea Stock (NASDAQ:OPT)Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More OPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPT Stock News HeadlinesApril 23, 2024 | americanbankingnews.comAnalyzing Opthea (NASDAQ:OPT) & Cellectis (NASDAQ:CLLS)April 13, 2024 | americanbankingnews.comFY2024 EPS Estimates for Opthea Limited Lowered by Analyst (NASDAQ:OPT)April 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 8, 2024 | globenewswire.comOpthea Appoints John Han, PharmD, as VP Medical AffairsApril 5, 2024 | nasdaq.comOpthea Limited American Depositary Shares (OPT)April 4, 2024 | globenewswire.comOpthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | msn.comWhy A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling todayApril 3, 2024 | globenewswire.comOpthea Appoints Sujal Shah to the Board of DirectorsApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 3, 2024 | investorplace.com7 Growth Stocks to Buy to Outperform the Nasdaq IndexMarch 19, 2024 | globenewswire.comOpthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024March 6, 2024 | msn.comEnd in sight as Opthea looks to be key player in US$10 billion wet AMD marketMarch 5, 2024 | globenewswire.comOpthea to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | globenewswire.comOpthea Reports Half-Year Financial Results and Business UpdatesFebruary 22, 2024 | au.finance.yahoo.comOpthea Limited (OPT)February 20, 2024 | finanznachrichten.deOpthea Limited: Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical AdvisorFebruary 19, 2024 | globenewswire.comOpthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical AdvisorFebruary 14, 2024 | finanznachrichten.deOpthea Limited: Opthea Completes Enrollment in First Pivotal Trial with SoziniberceptFebruary 14, 2024 | finance.yahoo.comOpthea Completes Enrollment in First Pivotal Trial with SoziniberceptFebruary 14, 2024 | globenewswire.comOpthea Completes Enrollment in First Pivotal Trial with SoziniberceptDecember 27, 2023 | msn.comWhy Is Retinal Diseases-Focused Opthea Stock Trading Higher Today?December 27, 2023 | msn.comOpthea to receive $35M commitment and additional $50M fundingDecember 27, 2023 | marketwatch.comOpthea Limited ADRs Rise 31% on Raised FundingDecember 27, 2023 | finance.yahoo.comOpthea to Receive US$35M Commitment and Additional US$50M FundingDecember 16, 2023 | msn.comOpthea Limited - ADR (OPT) Price Target Increased by 7.41% to 6.39December 1, 2023 | finance.yahoo.comOpthea to Present at the FLORetina 2023 CongressNovember 27, 2023 | msn.comOpthea Limited - ADR (OPT) Price Target Increased by 9.06% to 5.95See More Headlines Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OPT CUSIPN/A CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+314.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales1,794.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-33.80Miscellaneous Outstanding Shares58,400,000Free Float56,526,000Market Cap$197.39 million OptionableNot Optionable Beta1.19 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Megan Baldwin M.A.I.C.D. (Age 49)MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director Comp: $599.73kMs. Judith J. Robertson B.A. (Age 63)M.B.A., Chief Commercial Officer Comp: $588.59kMs. Karen Adams CPA (Age 52)VP of Finance & Company Secretary Comp: $305.14kDr. Frederic Guerard M.S. (Age 51)Pharm.D., Chief Executive Officer Mr. Peter F. Lang M.B.A. (Age 51)Chief Financial Officer Ms. Sarika Gulhar Ph.D.Executive Director of Human ResourcesDr. Michael Gerometta Ph.D. (Age 59)Head of Chemistry, Manufacturing & Controls Development Comp: $127.66kMr. Bruno Gagnon BPHARM (Age 55)M.Sc., Senior Vice President of Global Clinical Operations Dr. Kenneth SallChief Medical OfficerDr. Fang Li Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCardiff OncologyNASDAQ:CRDFKodiak SciencesNASDAQ:KODInnate PharmaNASDAQ:IPHACentury TherapeuticsNASDAQ:IPSCAcumen PharmaceuticalsNASDAQ:ABOSView All Competitors OPT Stock Analysis - Frequently Asked Questions Should I buy or sell Opthea stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPT shares. View OPT analyst ratings or view top-rated stocks. What is Opthea's stock price target for 2024? 2 analysts have issued 1-year target prices for Opthea's shares. Their OPT share price targets range from $12.00 to $16.00. On average, they expect the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for OPT or view top-rated stocks among Wall Street analysts. How have OPT shares performed in 2024? Opthea's stock was trading at $2.95 on January 1st, 2024. Since then, OPT shares have increased by 13.9% and is now trading at $3.36. View the best growth stocks for 2024 here. When did Opthea IPO? Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
